In the last trading session, 11.06 million Immunic Inc (NASDAQ:IMUX) shares changed hands as the company’s beta touched 1.85. With the company’s per share price at $1.40 changed hands at -$0.15 or -9.68% during last session, the market valuation stood at $126.11M. IMUX’s last price was a discount, traded about -50.71% off its 52-week high of $2.11. The share price had its 52-week low at $0.95, which suggests the last value was 32.14% up since then. When we look at Immunic Inc’s average trading volume, we note the 10-day average is 0.4 million shares, with the 3-month average coming to 382.19K.
Analysts gave the Immunic Inc (IMUX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended IMUX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Immunic Inc’s EPS for the current quarter is expected to be -0.22.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Immunic Inc (NASDAQ:IMUX) trade information
Instantly IMUX was in red as seen at the end of in last trading. With action -6.67%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -6.67%, with the 5-day performance at -6.67% in the red. However, in the 30-day time frame, Immunic Inc (NASDAQ:IMUX) is -12.50% down. Looking at the short shares, we see there were 2.68 million shares sold at short interest cover period of 4.77 days.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 72.0% from its current market value. According to analyst projections, IMUX’s forecast low is 5 with 5 as the target high. To hit the forecast high, the stock’s price needs a -257.14% plunge from its current level, while the stock would need to soar -257.14% for it to hit the projected low.
Immunic Inc (IMUX) estimates and forecasts
Data shows that the Immunic Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 12.90% over the past 6 months, a 54.50% in annual growth rate that is considerably higher than the industry average of 17.20%.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 10k. 4 analysts are of the opinion that Immunic Inc’s revenue for the current quarter will be 10k.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 31.12%. The 2024 estimates are for Immunic Inc earnings to increase by 56.87%, but the outlook for the next 5-year period is at 15.50% per year.
IMUX Dividends
Immunic Inc is expected to release its next quarterly earnings report in November.
Immunic Inc (NASDAQ:IMUX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.34% of Immunic Inc shares while 62.51% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 64.67%. There are 62.51% institutions holding the Immunic Inc stock share, with BVF INC/IL the top institutional holder. As of 2024-06-30, the company held 9.15% of the shares, roughly 8.9 million IMUX shares worth $9.88 million.
AVIDITY PARTNERS MANAGEMENT LP holds the second largest percentage of outstanding shares, with 9.15% or 8.9 million shares worth $9.88 million as of 2024-06-30.
